KATHERINE SPRINGMAN: Open Payments
NPI 1992162457 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$783 in 34 payments from 15 companies in 2025. Trend: 2023 $395 · 2024 $272 · 2025 $783
Food & beverage: $684Education: $99
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $179 |
| Aveo Pharmaceuticals, Inc. | 1 | $99 |
| Daiichi Sankyo Inc. | 4 | $84 |
| ABBVIE INC. | 3 | $74 |
| AstraZeneca Pharmaceuticals LP | 3 | $62 |
| PFIZER INC. | 3 | $54 |
| Genmab U.S., Inc. | 2 | $47 |
| GENZYME CORPORATION | 2 | $45 |
| Secura Bio, Inc. | 1 | $26 |
| PUMA BIOTECHNOLOGY, INC. | 1 | $21 |
Products named: FOTIVDA, KISQALI, Enhertu, Tivdak, LUTATHERA, DATROWAY, VENCLEXTA, PLUVICTO.
Industry payments across IN — which companies pay providers there.
